A cohort study found that for HR+/HER2- BC patients, compared with using fulvestrant alone, the combination of palbociclib and fulvestrant increased the risk of clinical adverse events such as neutropenia, leukopenia and thrombocytopenia [14]. The gene discussed is ERBB2; the disease is breast cancer.